Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

1.6K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.6K
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

978
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
978

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prevalence of Antiplatelet and Anticoagulation Therapy in Children with Sickle Cell Anemia and Stroke.

Pediatric stroke·2025
Same author

Real-world clinical utility of a multi-protein, blood-based biomarker assay for disease activity assessments in multiple sclerosis.

Multiple sclerosis journal - experimental, translational and clinical·2025
Same author

Post-infectious Transverse Myelitis Secondary to Hand, Foot, and Mouth Disease in a Pregnant Daycare Worker.

Cureus·2024
Same author

Cerebral Cavernous Malformation Associated With Left Middle Cerebral Artery (MCA) Aneurysm and Bilateral Internal Carotid Artery (ICA) Dissections.

Cureus·2023
Same author

Potential Cardiac Tamponade Development Secondary to SARS-CoV-2 Infection.

Current problems in cardiology·2022
Same author

Readmission Rates in Patients With Multiple Sclerosis: A Nationwide Cohort Study.

International journal of MS care·2022

Related Experiment Video

Updated: Jul 16, 2025

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients
12:23

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients

Published on: April 14, 2014

14.1K

Hospital Readmission Rates in Patients With Neuromyelitis Optica Spectrum Disorder.

Akhil Padarti1, Amod Amritphale2, William Kilgo1

  • 1From the Department of Neurology, Mobile, AL, USA (AP, WK).

International Journal of MS Care
|September 18, 2023
PubMed
Summary

Neuromyelitis optica spectrum disorder (NMOSD) readmission rates are 11.9%. Older age and certain comorbidities increase NMOSD readmission risk, while private insurance decreases it.

More Related Videos

Human Serum Anti-aquaporin-4 Immunoglobulin G Detection by Cell-based Assay
05:45

Human Serum Anti-aquaporin-4 Immunoglobulin G Detection by Cell-based Assay

Published on: April 5, 2019

23.4K
Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
09:29

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Published on: August 21, 2017

11.5K

Related Experiment Videos

Last Updated: Jul 16, 2025

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients
12:23

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients

Published on: April 14, 2014

14.1K
Human Serum Anti-aquaporin-4 Immunoglobulin G Detection by Cell-based Assay
05:45

Human Serum Anti-aquaporin-4 Immunoglobulin G Detection by Cell-based Assay

Published on: April 5, 2019

23.4K
Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
09:29

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Published on: August 21, 2017

11.5K

Area of Science:

  • Neurology
  • Immunology
  • Health Services Research

Background:

  • Neuromyelitis optica spectrum disorder (NMOSD) is a severe autoimmune astrocytopathy impacting the central nervous system.
  • Recurrent NMOSD flares necessitate immunomodulatory therapies and often lead to hospitalization and potential readmission.
  • Hospital readmission rates are key metrics for healthcare quality and impact financial reimbursement.

Purpose of the Study:

  • To identify patient characteristics and comorbidities associated with 30-day hospital readmissions in NMOSD patients.
  • To inform strategies for reducing readmission rates and improving patient outcomes in NMOSD.

Main Methods:

  • Analysis of the 2017 Nationwide Readmissions Database for NMOSD hospitalizations in the US.
  • Inclusion of all patients readmitted within 30 days of discharge from their initial NMOSD hospitalization.

Main Results:

  • The 30-day NMOSD all-cause readmission rate was 11.9%.
  • Increased readmission odds were linked to ages 65-74 and comorbidities like respiratory failure, peripheral vascular disease, neurocognitive disorders, and neurologic blindness.
  • Private insurance was associated with decreased readmission odds; plasma exchange increased readmission odds, while IVIg and immunomodulatory infusions did not significantly affect readmission.

Conclusions:

  • Neurologic, infectious, and respiratory causes were the primary drivers of 30-day NMOSD readmissions.
  • Targeted treatments addressing these common etiologies could potentially lower readmission rates and reduce the overall disease burden for NMOSD patients.